IDEAYA Biosciences IDYA
$25.56 −$0.61 (-2.33%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $25.56 0.00%
Open$25.83
Prev close$26.17
Day range$25.46 – $26.87
Volume1.11M
Market cap$2.47B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$10.24M-95.1% YoY
Operating profit-$137.63M-226.9% YoY
Net profit-$125.75M-205.5% YoY
Diluted EPS-$1.22-191.7% YoY
Free cash flow-$93.75M-165.9% YoY
Operating cash flow-$93.48M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Operating margin-1,267.3%
Net margin-1,149.6%
Return on equity-38.5%
Return on assets-35.0%
Return on invested capital-41.3%
Current ratio9.04
Liabilities / assets10.2%
Cash & investments$838.54M
Total debt$27.55M
Net cash (debt)$810.99M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $10.24M | $8.86M | $6.56M | $218.71M | $10.88M |
| Total Operating Revenue | $10.24M | $8.86M | $6.56M | $218.71M | $10.88M |
| Operating Expense | $147.87M | $131.15M | $115.10M | $378.02M | $105.45M |
| Selling and Admin Expenses | $26.30M | $22.46M | $19.38M | $63.32M | $18.85M |
| -General & Admin Expense | $26.30M | $22.46M | $19.38M | $63.32M | $18.85M |
| Research & Development | $121.58M | $108.69M | $95.73M | $314.70M | $86.60M |
| Operating Profit | -$137.63M | -$122.29M | -$108.54M | -$159.31M | -$94.57M |
| Net Non-Operating Interest Income (Expense) | $11.88M | $9.84M | $10.01M | $45.62M | $11.30M |
| Non-Operating Interest Income | $11.88M | $9.84M | $10.01M | $45.62M | $11.30M |
| Pretax Profit | -$125.75M | -$112.45M | -$98.54M | -$113.70M | -$83.27M |
| Net Profit | -$125.75M | -$112.45M | -$98.54M | -$113.70M | -$83.27M |
| Profit from Continuing Operations | -$125.75M | -$112.45M | -$98.54M | -$113.70M | -$83.27M |
| Net Income to Parent Company | -$125.75M | -$112.45M | -$98.54M | -$113.70M | -$83.27M |
| Net Income to Common Stockholders | -$125.75M | -$112.45M | -$98.54M | -$113.70M | -$83.27M |
| Basic EPS | -$1.22 | -$1.22 | -$1.11 | -$1.28 | -$0.94 |
| Diluted EPS | -$1.22 | -$1.22 | -$1.11 | -$1.28 | -$0.94 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $1.22B | $1.31B | $1.03B | $1.11B | $1.11B |
| Total Current Assets | $871.97M | $864.03M | $696.11M | $666.73M | $666.73M |
| Cash and Cash Equivalents & Short-Term Investments | $838.54M | $828.96M | $671.20M | $639.39M | $639.39M |
| -Cash and Cash Equivalents | $261.45M | $272.59M | $157.52M | $112.83M | $112.83M |
| -Short Term Investments | $577.09M | $556.37M | $513.68M | $526.56M | $526.56M |
| Receivables | $10.24M | $15.42M | $6.56M | $5.97M | $5.97M |
| -Other Receivables | $10.24M | $15.42M | $6.56M | $5.97M | $5.97M |
| Other Current Assets | $23.18M | $19.65M | $18.35M | $21.37M | $21.37M |
| Total Non-Current Assets | $344.06M | $445.67M | $334.24M | $442.60M | $442.60M |
| Net PPE | $29.58M | $30.46M | $31.25M | $31.29M | $31.29M |
| -Gross PPE | $45.83M | $46.09M | $46.19M | $45.54M | $45.54M |
| -Accumulated Depreciation | -$16.25M | -$15.63M | -$14.95M | -$14.26M | -$14.26M |
| Investments and Advances | $312.29M | $413.93M | $301.71M | $410.30M | $410.30M |
| -Available for Sale Securities | $312.29M | $413.93M | $301.71M | $410.30M | $410.30M |
| Other Non-Current Assets | $2.19M | $1.28M | $1.28M | $1.02M | $1.02M |
| Total Liabilities | $123.96M | $110.79M | $93.08M | $86.39M | $86.39M |
| Total Current Liabilities | $96.41M | $82.68M | $64.83M | $58.82M | $58.82M |
| Payables | $22.04M | $30.51M | $20.74M | $17.58M | $17.58M |
| -Accounts Payable | $22.04M | $30.51M | $20.74M | $17.58M | $17.58M |
| Current Accrued Expenses | $72.22M | $50.98M | $43.75M | $40.89M | $40.89M |
| Short-Term Debt and Capital Lease Obligation | $2.15M | $1.19M | $350,000.00 | $339,000.00 | $339,000.00 |
| -Current Capital Lease Obligation | $2.15M | $1.19M | $350,000.00 | $339,000.00 | $339,000.00 |
| Total Non-Current Liabilities | $27.55M | $28.12M | $28.25M | $27.58M | $27.58M |
| Long Term Debt and Capital Lease Obligation | $27.55M | $28.12M | $28.25M | $27.58M | $27.58M |
| -Long Term Capital Lease Obligation | $27.55M | $28.12M | $28.25M | $27.58M | $27.58M |
| Total Equity | $1.09B | $1.20B | $937.27M | $1.02B | $1.02B |
| Stockholders' Equity | $1.09B | $1.20B | $937.27M | $1.02B | $1.02B |
| Capital Stock | $10,000.00 | $10,000.00 | $9,000.00 | $9,000.00 | $9,000.00 |
| -Common Stock | $10,000.00 | $10,000.00 | $9,000.00 | $9,000.00 | $9,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $2.17B | $2.15B | $1.77B | $1.76B | $1.76B |
| Retained Earnings | -$1.07B | -$947.53M | -$835.08M | -$736.54M | -$736.54M |
| Gains/Losses Not Affecting Retained Earnings | -$4.88M | -$1.67M | -$494,000.00 | $2.27M | $2.27M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$93.48M | -$88.21M | -$75.17M | -$71.10M | -$90.50M |
| Net cash flow from continuing operations | -$93.48M | -$88.21M | -$75.17M | -$71.10M | -$90.50M |
| Net Income from Continuing Operations | -$125.75M | -$112.45M | -$98.54M | -$113.70M | -$83.27M |
| Depreciation & Depletion & Amortization | $1.03M | $1.12M | $1.14M | $4.59M | $1.20M |
| Change in Working Capital | $14.72M | $7.48M | $8.90M | $1.87M | -$18.69M |
| -Change in Prepaid Assets | -$4.57M | -$1.05M | $3.03M | -$7.84M | -$5.56M |
| -Change in Payables and Accrued Expense | $13.72M | $16.68M | $5.78M | $13.12M | -$5.66M |
| -Change in Other Current Liabilities | $396,000.00 | $707,000.00 | $686,000.00 | $2.56M | $669,000.00 |
| -Change In Other Working Capital | $5.18M | -$8.86M | -$587,000.00 | -$5.97M | -$8.14M |
| Net cash flow from investing | $78.65M | -$155.93M | $118.95M | $69.98M | -$97.53M |
| Net Cash Flow from Continuing Investing Activities | $78.65M | -$155.93M | $118.95M | $69.98M | -$97.53M |
| Net PPE Purchase and Sale | -$273,000.00 | -$866,000.00 | -$967,000.00 | -$2.37M | -$333,000.00 |
| Net Investment Purchase and Sale | $78.92M | -$155.07M | $119.92M | $72.34M | -$97.19M |
| Financing Cash Flow | $3.70M | $359.21M | $1.18M | $29.78M | $2.13M |
| Net Cash Flow from Continuing Financing Activities | $3.70M | $359.21M | $1.18M | $29.78M | $2.13M |
| Net Common Stock Issuance | -$1.18M | $216.44M | -$9,000.00 | $24.86M | -$46,000.00 |
| Proceeds from Stock Option Exercised | $4.88M | $142.77M | $1.19M | $4.92M | $2.18M |
| Ending Cash Balance | $262.73M | $273.87M | $158.80M | $113.84M | $113.84M |
| Net Change in Cash | -$11.14M | $115.07M | $44.96M | $28.66M | -$185.89M |
| Beginning Cash Balance | $273.87M | $158.80M | $113.84M | $85.18M | $299.73M |
| Free Cash Flow | -$93.75M | -$89.08M | -$76.14M | -$73.47M | -$90.83M |
| -Change in Receivables | – | – | – | $0.00 | – |
No comments yet — be the first to weigh in on IDYA.
Sign in to join the discussion.